Table 2 Phenotypic and molecular characteristics of S. aureus isolates among drug users in Guangzhou, China, 2017
Characteristics | S. aureus (N = 53) | ||
|---|---|---|---|
Total | MRSA(N = 24) | MSSA (N = 29) | |
Resistant phenotype (resistant) | |||
 Clindamycin | 24 (45.28) | 15 (62.50) | 9 (31.03) |
 Erythromycin | 26 (49.06) | 15 (62.50) | 11 (37.93) |
 Penicillin | 49 (92.45) | 23 (95.83) | 26 (89.66) |
 Linezolid | 1 (1.89) | 1 (4.17) | 0 (0.00) |
 Gentamicin | 4 (7.55) | 3 (12.50) | 1 (3.45) |
 Teicoplanin | 10 (18.87) | 8 (33.33) | 2 (6.90) |
 Trimethoprim-sulfamethoxazole | 7 (13.21) | 4 (16.67) | 3 (10.34) |
 Moxifloxacin | 5 (9.43) | 4 (16.67) | 1 (3.45) |
 Rifampin | 2 (3.77) | 2 (8.33) | 0 (0.00) |
 Chloramphenicol | 11 (20.75) | 7 (29.17) | 4 (13.79) |
 Tetracycline | 17 (32.08) | 9 (37.50) | 8 (27.59) |
Resistant genotype (positive) | |||
 erm(A) | 1 (1.89) | 1 (4.17) | 0 (0.00) |
 erm(C) | 5 (9.43) | 5 (20.83) | 0 (0.00) |
 tet(K) | 4 (7.55) | 4 (16.67) | 0 (0.00) |
 tet(M) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
Virulence genes (positive) | |||
 lukF-PV and lukS-PV | 3 (5.66) | 3 (12.50) | 0 (0.00) |
 tst | 2 (3.77) | 2 (8.33) | 0 (0.00) |
 eta | 1 (1.89) | 1 (4.17) | 0 (0.00) |
 etb | 1 (1.89) | 1 (4.17) | 0 (0.00) |
 sea | 0 (0.00) | 0 (0.00) | 0 (0.00) |
 seb | 1 (1.89) | 0 (0.00) | 1 (3.45) |
 sec | 3 (5.66) | 1 (4.17) | 2 (6.90) |
 sed | 17 (32.08) | 11 (45.83) | 6 (20.69) |
 see | 0 (0.00) | 0 (0.00) | 0 (0.00) |
 seg | 26 (49.06) | 13 (54.17) | 13 (44.83) |
 seh | 3 (3.45) | 3 (12.50) | 0 (0.00) |
 sei | 18 (33.96) | 9 (37.50) | 9 (31.03) |
 sej | 6 (11.32) | 3 (12.50) | 3 (10.34) |
 sek | 11 (20.75) | 8 (33.33) | 3 (10.34) |
 sel | 4 (7.55) | 2 (8.33) | 2 (6.90) |
 sem | 16 (30.19) | 6 (25.00) | 10 (34.48) |
 sen | 12 (22.64) | 4 (16.67) | 8 (27.59) |
 seo | 13 (24.53) | 4 (16.67) | 9 (31.03) |
 sep | 4 (7.55) | 1 (4.17) | 3 (10.34) |
 seq | 5 (9.43) | 2 (8.33) | 3 (10.34) |
 ser | 5 (9.43) | 2 (8.33) | 3 (10.34) |
 seu | 12 (22.64) | 7 (29.17) | 5 (17.24) |